CVS Health's Caremark business signed a new pharmacy benefits contract with the California Public Employees' Retirement System, known as Calpers.
Headwinds galore from regulatory scrutiny, Medicare Advantage costs, and management changes, but insiders are buying, and the valuation is historically cheap. Q2 earnings are likely to be the trough. Clarity on regulatory scrutiny and the potential for renewed share buybacks or guidance could be catalysts for the stock post-earnings.
In the latest trading session, UnitedHealth Group (UNH) closed at $300.58, marking a -1.16% move from the previous day.
UNH relies on its growing commercial insurance business as pressures from Medicare mount and industry headwinds persist.
For years now, UnitedHealth Group has been the first of the major health insurers to report its quarterly earnings. And Wall Street analysts and investors have looked to the healthcare giant -- which owns the nation's largest health insurer – for clues on how the sector is doing.
UnitedHealth Group (UNH 1.42%) faces a series of unprecedented challenges, from leadership crises to federal investigations, leading to a significant stock decline. Is this the end of its dominance?
CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
UnitedHealth (UNH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The investigation, which dates back to at least last summer, concerns alleged efforts to encourage staffers to record certain diagnoses that trigger higher payments under Medicare Advantage, according to a report.
Let's get the bad news out of the way first. The Eden Prairie, Minn.
Former employees at UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) are being questioned by the US Department of Justice (DOJ) as part of its ongoing criminal investigation into the company's Medicare Advantage billing practices, according to a Wall Street Journal report. Prosecutors from the DOJ's healthcare-fraud unit, along with the FBI and the Department of Health and Human Services' Office of Inspector General, have been interviewing former doctors, nurses, and other staff about how UnitedHealth deployed medical personnel to collect diagnoses that increased Medicare reimbursements, the publication reported.